サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1385640

線維芽細胞増殖因子の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 製品別、用途別、エンドユーザー別、地域別

Fibroblast Growth Factors Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America & Middle East & Africa)
出版日: | 発行: Fairfield Market Research | ページ情報: 英文 235 Pages | 納期: 2～5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.94円
線維芽細胞増殖因子の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 製品別、用途別、エンドユーザー別、地域別
出版日: 2023年11月16日
発行: Fairfield Market Research
ページ情報: 英文 235 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

世界の線維芽細胞増殖因子（FGF）の市場規模は、2024年に2億8,000万米ドルになるとみられており、今後10年間で力強い成長が見込まれています。同市場は今後、8.64%のCAGRで拡大し、2031年末には、5億米ドルに達すると予測されています。FGFは細胞増殖、分化、創傷治癒、組織維持において極めて重要な役割を果たしており、様々な医療用途において極めて重要なものとなっています。

FGFは、特に皮膚、筋肉、腱、骨、歯、神経といった組織の再生と治癒において、医療治療における重要性が高まっています。FGFを幹細胞や特殊な素材と組み合わせることで、怪我や病気からの回復プロセスに革命をもたらす可能性を秘めています。

分子科学の進歩により、創傷治癒メカニズムが包括的に理解されるようになっています。この知識により、瘢痕のない創傷治癒や幹細胞前駆体からの組織移植への道が開かれ、患者ケアの向上が期待されます。

米国では様々ながんが急増しており、特にがん治療におけるFGFの需要を牽引しています。乳がんと胃がんの流行がこの需要に大きく寄与しています。

ドイツはバイオテクノロジーと再生医療の最前線にあり、FGFの変革の可能性に注目しています。特に慢性創傷、筋骨格系障害、神経疾患の治療において、学界、バイオテクノロジー企業、政府機関の共同研究がFGFの需要を牽引しています。

当レポートでは、世界の線維芽細胞増殖因子市場について調査し、市場の概要とともに、製品別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の線維芽細胞増殖因子市場の見通し、2018年～2031年

  • 世界の線維芽細胞増殖因子市場の見通し、製品別、金額（100万米ドル）、2018年～2031年
  • 世界の線維芽細胞増殖因子市場の見通し、用途別、金額（100万米ドル）、2018年～2031年
  • 世界の線維芽細胞増殖因子市場の見通し、エンドユーザー別、金額（100万米ドル）、2018年～2031年
  • 世界の線維芽細胞増殖因子市場の見通し、地域別、金額（100万米ドル）、2018年～2031年

第4章 北米の線維芽細胞増殖因子市場の見通し、2018年～2031年

第5章 欧州の線維芽細胞増殖因子市場の見通し、2018年～2031年

第6章 アジア太平洋の線維芽細胞増殖因子市場の見通し、2018年～2031年

第7章 ラテンアメリカの線維芽細胞増殖因子市場の見通し、2018年～2031年

第8章 中東・アフリカの線維芽細胞増殖因子市場の見通し、2018年～2031年

第9章 競合情勢

  • エンドユーザー別と用途別のヒートマップ
  • 企業の市場シェア分析、2023年
  • 競争力ダッシュボード
  • 企業プロファイル
    • Thermo Fisher Scientific
    • Sigma-Aldrich (now part of Merck KGaA)
    • PeproTech
    • R&D Systems (a Bio-Techne brand)
    • Abcam
    • Cell Signaling Technology
    • Novus Biologicals

第10章 付録

目次

The global fibroblast growth factors (FGFs) market, which was valued at $280 million in 2024, is expected to experience robust growth over the next decade, with a projected CAGR of 8.64%. By the end of 2031, the market is anticipated to reach a valuation of $500 million. FGFs play a pivotal role in cellular proliferation, differentiation, wound healing, and tissue maintenance, making them crucial in various medical applications.

The Rising Significance of FGFs in the Medical Field

FGFs have gained increasing importance in medical treatments, particularly in regenerating and healing tissues such as skin, muscles, tendons, bones, teeth, and nerves. The combination of FGFs with stem cells and specialized materials holds the potential to revolutionize the recovery process from injuries and diseases.

Factors Boosting the Importance of Fibroblast Growth Factors

In-Depth Understanding of Wound Healing Mechanisms: Advances in molecular science have led to a comprehensive understanding of wound healing mechanisms. This knowledge is expected to pave the way for scar-free wound healing and tissue transplantation from stem cell precursors, enhancing patient care.

Challenges Hindering Sales Growth of Fibroblast Growth Factors

High Development and Production Costs: The complex process of developing and producing FGFs involves significant financial investments. From extensive research to preclinical testing and clinical trials, the costs associated with FGF development pose challenges to their widespread adoption.

Country-Specific Insights

United States: The United States is experiencing a surge in various carcinomas, driving the demand for FGFs, especially in cancer treatment. The prevalence of breast and stomach cancers has significantly contributed to this demand.

According to the American Society of Clinical Oncology (ASCO), approximately 297,790 women in the U.S. are expected to be diagnosed with invasive breast cancer in 2023. Additionally, stomach cancer cases are projected to reach around 26,500, with 15,930 in men and 10,570 in women in 2022.

The need for fibroblast growth factors and cytokines in the treatment of various carcinomas, coupled with government initiatives to promote research, is propelling the demand for FGFs in the United States.

Germany: Germany is at the forefront of biotechnology and regenerative medicine, focusing on the transformative potential of FGFs. Collaborations between academia, biotech companies, and government bodies are driving demand for FGFs, particularly in the treatment of chronic wounds, musculoskeletal disorders, and neurological conditions.

China: FGFs are emerging as promising targets for cancer treatment in China. Researchers are exploring FGFs' potential to disrupt tumor growth and angiogenesis, offering new avenues for cancer therapies. The country's robust biopharmaceutical industry and collaborative research initiatives are accelerating the development of FGF-targeted therapies.

Competition Landscape

The global fibroblast growth factors market is characterized by a consolidated competitive landscape, with a few key players offering products and services on a global scale. Companies in this market are focusing on research and development, product launches, and strategic mergers to meet customer expectations and strengthen their market position.

Key Companies in the Market

  • Thermo Fisher Scientific
  • Sigma-Aldrich (now part of Merck KGaA)
  • PeproTech
  • R&D Systems (a Bio-Techne brand)
  • Abcam
  • Cell Signaling Technology
  • Novus Biologicals

Key Segments of Fibroblast Growth Factors Industry Research

Product:

  • FGF1
  • FGF2
  • FGF3
  • FGF4
  • FGF7
  • FGF10
  • FGF11
  • FGF12
  • FGF13
  • FGF14
  • FGF15
  • FGF18
  • FGF19
  • FGF20
  • FGF23
  • Others

Application:

  • Oncology
  • Hematology
  • Wound Healing
  • Dermatology
  • Cardiovascular Disease & Diabetes
  • Cell Culture
  • Others

End User:

  • Pharmaceutical & Biotechnology Companies
  • Research Centers & Academic Institutes
  • CMOs & CDMOs

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Fibroblast Growth Factors Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Fibroblast Growth Factors Market Outlook, 2018 - 2031

  • 3.1. Global Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. FGF1
      • 3.1.1.2. FGF2
      • 3.1.1.3. FGF3
      • 3.1.1.4. FGF4
      • 3.1.1.5. FGF7
      • 3.1.1.6. FGF10
      • 3.1.1.7. FGF11
      • 3.1.1.8. FGF12
      • 3.1.1.9. FGF13
      • 3.1.1.10. FGF14
      • 3.1.1.11. FGF15
      • 3.1.1.12. FGF18
      • 3.1.1.13. FGF19
      • 3.1.1.14. FGF20
      • 3.1.1.15. FGF23
      • 3.1.1.16. Others
  • 3.2. Global Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Oncology
      • 3.2.1.2. Hematology
      • 3.2.1.3. Wound Healing
      • 3.2.1.4. Dermatology
      • 3.2.1.5. Cardiovascular Disease & Diabetes
      • 3.2.1.6. Cell Culture
      • 3.2.1.7. Others
  • 3.3. Global Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Pharmaceutical & Biotechnology Companies
      • 3.3.1.2. Research Centers & Academic Institutes
      • 3.3.1.3. CMOs & CDMOs
  • 3.4. Global Fibroblast Growth Factors Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Fibroblast Growth Factors Market Outlook, 2018 - 2031

  • 4.1. North America Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. FGF1
      • 4.1.1.2. FGF2
      • 4.1.1.3. FGF3
      • 4.1.1.4. FGF4
      • 4.1.1.5. FGF7
      • 4.1.1.6. FGF10
      • 4.1.1.7. FGF11
      • 4.1.1.8. FGF12
      • 4.1.1.9. FGF13
      • 4.1.1.10. FGF14
      • 4.1.1.11. FGF15
      • 4.1.1.12. FGF18
      • 4.1.1.13. FGF19
      • 4.1.1.14. FGF20
      • 4.1.1.15. FGF23
      • 4.1.1.16. Others
  • 4.2. North America Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Oncology
      • 4.2.1.2. Hematology
      • 4.2.1.3. Wound Healing
      • 4.2.1.4. Dermatology
      • 4.2.1.5. Cardiovascular Disease & Diabetes
      • 4.2.1.6. Cell Culture
      • 4.2.1.7. Others
  • 4.3. North America Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Pharmaceutical & Biotechnology Companies
      • 4.3.1.2. Research Centers & Academic Institutes
      • 4.3.1.3. CMOs & CDMOs
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 4.4.1.2. U.S. Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 4.4.1.3. U.S. Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
      • 4.4.1.4. Canada Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 4.4.1.5. Canada Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 4.4.1.6. Canada Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Fibroblast Growth Factors Market Outlook, 2018 - 2031

  • 5.1. Europe Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. FGF1
      • 5.1.1.2. FGF2
      • 5.1.1.3. FGF3
      • 5.1.1.4. FGF4
      • 5.1.1.5. FGF7
      • 5.1.1.6. FGF10
      • 5.1.1.7. FGF11
      • 5.1.1.8. FGF12
      • 5.1.1.9. FGF13
      • 5.1.1.10. FGF14
      • 5.1.1.11. FGF15
      • 5.1.1.12. FGF18
      • 5.1.1.13. FGF19
      • 5.1.1.14. FGF20
      • 5.1.1.15. FGF23
      • 5.1.1.16. Others
  • 5.2. Europe Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Oncology
      • 5.2.1.2. Hematology
      • 5.2.1.3. Wound Healing
      • 5.2.1.4. Dermatology
      • 5.2.1.5. Cardiovascular Disease & Diabetes
      • 5.2.1.6. Cell Culture
      • 5.2.1.7. Others
  • 5.3. Europe Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Pharmaceutical & Biotechnology Companies
      • 5.3.1.2. Research Centers & Academic Institutes
      • 5.3.1.3. CMOs & CDMOs
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.4.1.2. Germany Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.3. Germany Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.4. U.K. Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.4.1.5. U.K. Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.6. U.K. Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.7. France Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.4.1.8. France Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.9. France Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.10. Italy Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.4.1.11. Italy Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.12. Italy Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.13. Turkey Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.4.1.14. Turkey Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.15. Turkey Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.16. Russia Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.4.1.17. Russia Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.18. Russia Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Fibroblast Growth Factors Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. FGF1
      • 6.1.1.2. FGF2
      • 6.1.1.3. FGF3
      • 6.1.1.4. FGF4
      • 6.1.1.5. FGF7
      • 6.1.1.6. FGF10
      • 6.1.1.7. FGF11
      • 6.1.1.8. FGF12
      • 6.1.1.9. FGF13
      • 6.1.1.10. FGF14
      • 6.1.1.11. FGF15
      • 6.1.1.12. FGF18
      • 6.1.1.13. FGF19
      • 6.1.1.14. FGF20
      • 6.1.1.15. FGF23
      • 6.1.1.16. Others
  • 6.2. Asia Pacific Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Oncology
      • 6.2.1.2. Hematology
      • 6.2.1.3. Wound Healing
      • 6.2.1.4. Dermatology
      • 6.2.1.5. Cardiovascular Disease & Diabetes
      • 6.2.1.6. Cell Culture
      • 6.2.1.7. Others
  • 6.3. Asia Pacific Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Pharmaceutical & Biotechnology Companies
      • 6.3.1.2. Research Centers & Academic Institutes
      • 6.3.1.3. CMOs & CDMOs
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 6.4.1.2. China Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.3. China Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.4. Japan Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 6.4.1.5. Japan Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.6. Japan Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.7. South Korea Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 6.4.1.8. South Korea Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.9. South Korea Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.10. India Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 6.4.1.11. India Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.12. India Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Fibroblast Growth Factors Market Outlook, 2018 - 2031

  • 7.1. Latin America Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. FGF1
      • 7.1.1.2. FGF2
      • 7.1.1.3. FGF3
      • 7.1.1.4. FGF4
      • 7.1.1.5. FGF7
      • 7.1.1.6. FGF10
      • 7.1.1.7. FGF11
      • 7.1.1.8. FGF12
      • 7.1.1.9. FGF13
      • 7.1.1.10. FGF14
      • 7.1.1.11. FGF15
      • 7.1.1.12. FGF18
      • 7.1.1.13. FGF19
      • 7.1.1.14. FGF20
      • 7.1.1.15. FGF23
      • 7.1.1.16. Others
  • 7.2. Latin America Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
      • 7.2.1.1. Oncology
      • 7.2.1.2. Hematology
      • 7.2.1.3. Wound Healing
      • 7.2.1.4. Dermatology
      • 7.2.1.5. Cardiovascular Disease & Diabetes
      • 7.2.1.6. Cell Culture
      • 7.2.1.7. Others
  • 7.3. Latin America Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Pharmaceutical & Biotechnology Companies
      • 7.3.1.2. Research Centers & Academic Institutes
      • 7.3.1.3. CMOs & CDMOs
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 7.4.1.2. Brazil Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 7.4.1.3. Brazil Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.4.1.4. Mexico Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 7.4.1.5. Mexico Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 7.4.1.6. Mexico Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.4.1.7. Argentina Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 7.4.1.8. Argentina Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 7.4.1.9. Argentina Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Fibroblast Growth Factors Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. FGF1
      • 8.1.1.2. FGF2
      • 8.1.1.3. FGF3
      • 8.1.1.4. FGF4
      • 8.1.1.5. FGF7
      • 8.1.1.6. FGF10
      • 8.1.1.7. FGF11
      • 8.1.1.8. FGF12
      • 8.1.1.9. FGF13
      • 8.1.1.10. FGF14
      • 8.1.1.11. FGF15
      • 8.1.1.12. FGF18
      • 8.1.1.13. FGF19
      • 8.1.1.14. FGF20
      • 8.1.1.15. FGF23
      • 8.1.1.16. Others
  • 8.2. Middle East & Africa Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Oncology
      • 8.2.1.2. Hematology
      • 8.2.1.3. Wound Healing
      • 8.2.1.4. Dermatology
      • 8.2.1.5. Cardiovascular Disease & Diabetes
      • 8.2.1.6. Cell Culture
      • 8.2.1.7. Others
  • 8.3. Middle East & Africa Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Pharmaceutical & Biotechnology Companies
      • 8.3.1.2. Research Centers & Academic Institutes
      • 8.3.1.3. CMOs & CDMOs
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 8.4.1.2. GCC Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.3. GCC Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.4. South Africa Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 8.4.1.5. South Africa Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.6. South Africa Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.7. Egypt Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 8.4.1.8. Egypt Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.9. Egypt Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.10. Nigeria Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 8.4.1.11. Nigeria Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.12. Nigeria Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By End User vs by Application Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Thermo Fisher Scientific
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Sigma-Aldrich (now part of Merck KGaA)
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. PeproTech
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. R&D Systems (a Bio-Techne brand)
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Abcam
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Cell Signaling Technology
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Novus Biologicals
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations